NSABP Foundation
NSABP is a pioneering cancer research organization dedicated to advancing treatments and improving patient outcomes through clinical trials and research in breast and colorectal cancers. With a history spanning over 60 years, NSABP has led significant studies that have set new standards of care, saving millions of patients from invasive procedures and unnecessary treatments. The organization also engages in community support, education, and policy development to foster better understanding and management of cancer.
Industries
Nr. of Employees
medium (51-250)
NSABP Foundation
Pittsburgh, Pennsylvania, United States, North America
Patents
Services
Coordination and operational management of multicenter clinical trials across institutions for breast and colorectal cancer studies.
Protocol writing and study design services for randomized, open-label, double-blind, and platform trials.
Coordination of clinical validation studies for biomarker assays, including ctDNA-based MRD detection studies.
Safety assessment and monitoring for investigational therapies, including organ-specific safety studies.
Provision of governance documents, policy templates, and administrative forms to support site onboarding, personnel updates, and collaborator agreements.
Coordination and operational management of multicenter clinical trials across institutions for breast and colorectal cancer studies.
Protocol writing and study design services for randomized, open-label, double-blind, and platform trials.
Coordination of clinical validation studies for biomarker assays, including ctDNA-based MRD detection studies.
Safety assessment and monitoring for investigational therapies, including organ-specific safety studies.
Provision of governance documents, policy templates, and administrative forms to support site onboarding, personnel updates, and collaborator agreements.
Expertise Areas
- Clinical trial management
- Multicenter research network operations
- Breast cancer clinical research
- Colorectal cancer clinical research
Key Technologies
- Circulating tumor DNA (ctDNA) assays
- Minimal residual disease (MRD) detection
- Randomized controlled trial methodology
- Platform/adaptive trial methodologies